The Need For Physiological Phenotyping To Develop New Drugs For Airways Disease.

Chapman, DG; King, GG; Robinson, PD; Farah, CS; Thamrin, C

The Need For Physiological Phenotyping To Develop New Drugs For Airways Disease.

Chapman, DG King, GG Robinson, PD Farah, CS Thamrin, C

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Pharmacol Res, 2020, pp. 105029
Issue Date:: 2020-06-18

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

The embargo period expires on 30 Sep 2021

Adobe PDF

Download Accepted manuscriptAdobe PDF (1.28 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Chapman, DG
dc.contributor.author	King, GG
dc.contributor.author	Robinson, PD
dc.contributor.author	Farah, CS
dc.contributor.author	Thamrin, C
dc.date.accessioned	2020-06-26T04:53:36Z
dc.date.available	2020-06-12
dc.date.available	2020-06-26T04:53:36Z
dc.date.issued	2020-06-18
dc.identifier.citation	Pharmacol Res, 2020, pp. 105029
dc.identifier.issn	1043-6618
dc.identifier.issn	1096-1186
dc.identifier.uri	http://hdl.handle.net/10453/141675
dc.description.abstract	Asthma and COPD make up the majority of obstructive airways diseases (OADs), which affects ∼11% of the population. The main drugs used to treat OADs have not changed in the past five decades, with advancements mainly comprising variations on existing treatments. The recent biologics are beneficial to only specific subsets of patients. Part of this may lie in our inability to adequately characterise the tremendous heterogeneity in every aspect of OAD. The field is currently moving towards the concept of personalised medicine, based on a focus on treatable traits that are objective, measurable and modifiable. We propose extending this concept via the use of emerging clinical tools for comprehensive physiological phenotyping. We describe, based on published data, the evidence for the use of functional imaging, gas washout techniques and oscillometry, as well as potential future applications, to more comprehensively assess and predict treatment response in OADs. In this way, we hope to demonstrate how physiological phenotyping tools will improve the way in which drugs are prescribed, but most importantly, will facilitate development of new drugs for OADs.
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Pharmacol Res
dc.relation.isbasedon	10.1016/j.phrs.2020.105029
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.title	The Need For Physiological Phenotyping To Develop New Drugs For Airways Disease.
dc.type	Journal Article
utslib.location.activity	Netherlands
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	open_access	*
utslib.copyright.embargo	2021-09-30T00:00:00+1000Z
dc.date.updated	2020-06-26T04:53:30Z
pubs.publication-status	Published online

Abstract:

Asthma and COPD make up the majority of obstructive airways diseases (OADs), which affects ∼11% of the population. The main drugs used to treat OADs have not changed in the past five decades, with advancements mainly comprising variations on existing treatments. The recent biologics are beneficial to only specific subsets of patients. Part of this may lie in our inability to adequately characterise the tremendous heterogeneity in every aspect of OAD. The field is currently moving towards the concept of personalised medicine, based on a focus on treatable traits that are objective, measurable and modifiable. We propose extending this concept via the use of emerging clinical tools for comprehensive physiological phenotyping. We describe, based on published data, the evidence for the use of functional imaging, gas washout techniques and oscillometry, as well as potential future applications, to more comprehensively assess and predict treatment response in OADs. In this way, we hope to demonstrate how physiological phenotyping tools will improve the way in which drugs are prescribed, but most importantly, will facilitate development of new drugs for OADs.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/141675